Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Deregulated Expression of Circular RNAs in Acute Myeloid Leukemia

Susanne Lux, MSc, Tamara J. Blätte, MSc, Sibylle Cocciardi, MSc, Klaus Schwarz, MD, Hartmut Döhner, MD, Konstanze Döhner, MD, Lars Bullinger, MD, Anna Dolnik, PhD

Blood (2018) 132 (Supplement 1): 3894.

https://doi.org/10.1182/blood-2018-99-113333

Published: 2018

Journal Articles

NGS-Based Monitoring of Measurable Residual Disease in FLT3 -ITD Positive Acute Myeloid Leukemia

Tamara J. Blätte, MSc, Laura K. Schmalbrock, MD, Sabrina Skambraks, Sibylle Cocciardi, MSc, Anna Dolnik, PhD, Konstanze Döhner, MD, Lars Bullinger, MD

Blood (2018) 132 (Supplement 1): 2778.

https://doi.org/10.1182/blood-2018-99-113382

Published: 2018

Journal Articles

Assessment of the Genomic Landscape of Intermediate Risk Acute Myeloid Leukemia As Defined By 2010 ELN Risk Classification

Blood (2018) 132 (Supplement 1): 994.

https://doi.org/10.1182/blood-2018-99-114671

Published: 2018

Journal Articles

BRCA1/2 Containing Complex 3 ( BRCC36 ) Is Recurrently Mutated in AML with t(8;21) and Associated with Increased Sensitivity to Chemotherapy through Impairment of the DNA Damage Repair Pathway

Tatjana Meyer, MSc, Nikolaus Jahn, MD, Anna Dolnik, PhD, Peter Paschka, MD, Verena I. Gaidzik, MD, Daniela Weber, MSc, Lars Bullinger, MD, Hartmut Döhner, MD, Konstanze Döhner, MD, Jan Kroenke, MD

Blood (2018) 132 (Supplement 1): 1487.

https://doi.org/10.1182/blood-2018-99-114143

Published: 2018

Journal Articles

Comprehensive Molecular Profiling of FLT3 -Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603)

Blood (2018) 132 (Supplement 1): 1534.

https://doi.org/10.1182/blood-2018-99-115842

Published: 2018

Journal Articles

Genetic Heterogeneity of t(8;21)(q22;q22.1) Acute Myeloid Leukemia Revealed By High-Throughput Targeted Sequencing

Blood (2017) 130 (Supplement 1): 2688.

https://doi.org/10.1182/blood.V130.Suppl_1.2688.2688

Published: 2017

Journal Articles

Clonal Evolution of FLT3 -ITD Positive AML in Patients Treated with Midostaurin in Combination with Chemotherapy within the Ratify (CALGB 10603) and AMLSG 16-10 Trials

Blood (2017) 130 (Supplement 1): 182.

https://doi.org/10.1182/blood.V130.Suppl_1.182.182

Published: 2017

Journal Articles

Whole Exome Sequencing Reveals High Genetic Diversity in Relapsed Multiple Myeloma

Laura K. Schmalbrock, MD, Stephan Bohl, MD, Anna Dolnik, PhD, Tamara J. Blätte, MSc, Maria-Veronica Teleanu, Miriam Kull, MD, Denise Miller, Lars Bullinger, MD, Christian Langer, MD, Jan Kronke

Blood (2017) 130 (Supplement 1): 4363.

https://doi.org/10.1182/blood.V130.Suppl_1.4363.4363

Published: 2017

Journal Articles

High-Resolution SNP-Array Profiling of "Ultra-High Risk" CLL Cases Reveals New Recurrent Genomic Alterations

Jennifer Edelmann, MD PhD, Karlheinz Holzmann, Dr. rer. nat., Eugen Tausch, MD, Anna Dolnik, PhD, Tamara J. Blätte, MSc, Stefan Ibach, Dr, Jenny Saub, Daniel Mertens, PhD, Lars Bullinger, MD, Kirsten Fischer, MD, Valentin Goede, MD, John G. Gribben, MDDSc FMedSci, Michael J. Hallek, MD, Hartmut Döhner, MD, Stephan Stilgenbauer, MD PhD

Blood (2017) 130 (Supplement 1): 2992.

https://doi.org/10.1182/blood.V130.Suppl_1.2992.2992

Published: 2017

Journal Articles

Circular RNAs of the Nucleophosmin 1 ( NPM1 ) Gene in Acute Myeloid Leukemia Patients

Susanne Hirsch, MSc, Tamara J. Blätte, MSc, Sarah Grasedieck, MSc, Arefeh Rouhi, PhD, Mojca Jongen-Lavrencic, MD PhD, Florian Kuchenbauer, Peter Paschka, MD, Verena I. Gaidzik, MD, Konstanze Döhner, MD, Sibylle Cocciardi, MSc, Anna Dolnik, PhD, Lars Bullinger, MD

Blood (2016) 128 (22): 2695.

https://doi.org/10.1182/blood.V128.22.2695.2695

Published: 2016

Journal Articles

Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR)

Lin Tang, PhD, Anna Dolnik, PhD, Kyle J. MacBeth, PhD, Hervé Dombret, Prof., John F. Seymour, MD, Mark D. Minden, MD PhD, Richard M. Stone, MD, C.L. Beach, PharmD, Hartmut Döhner, MD, Lars Bullinger, MD

Blood (2016) 128 (22): 2859.

https://doi.org/10.1182/blood.V128.22.2859.2859

Published: 2016

Journal Articles

Analysis of the PD-1/PD-L1 Axis Points to Association of Unfavorable Recurrent Mutations with PD-L1 Expression in AML

Malgorzata Zajac, PhD, Joanna Zaleska, Anna Dolnik, PhD, Anna Siwiec, PhD, Olga Jankowska-Lecka, PhD, Radoslaw Mlak, PhD, Marzanna Ciesielka, PhD, Tomasz Gromek, MD PhD, Bozena Sokolowska, MD PhD, Norbert Grzasko, MD PhD, Maria Soroka-Wojtaszko, MD PhD, Aneta Szudy-Szczyrek, MD, Maria Majdan, MD, Marek Hus, MD PhD, Lars Bullinger, MD, Krzysztof Giannopoulos, MD PhD

Blood (2016) 128 (22): 1685.

https://doi.org/10.1182/blood.V128.22.1685.1685

Published: 2016

Journal Articles

In Vivo modeling of Resistance to PI3Kδ Inhibitor Treatment Using EµTCL1-Tg Tumor Transfer Model

Annika Scheffold, Billy Michael Chelliah Jebaraj, Eugen Tausch, Anella Yahiaoui, Anna Dolnik, PhD, Tamara Jacqueline Blaette, M.sc., Lars Bullinger, MD, Christof Schneider, MD, Daniel Mertens, PhD, Veerendra Munugalavadla, Shih-Shih Chen, PhD, Nicholas Chiorazzi, MD, Stacey Tannheimer, Hartmut Döhner, MD, Stephan Stilgenbauer

Blood (2016) 128 (22): 190.

https://doi.org/10.1182/blood.V128.22.190.190

Published: 2016

Journal Articles

Clonal Evolution in NPM1 Mutated Acute Myeloid Leukemia (AML)

Silke Kapp-Schwoerer, MD, Sibylle Cocciardi, Jan Kroenke, MD, Anna Dolnik, PhD, Tamara J. Blätte, Andrea Corbacioglu, PhD, Verena I. Gaidzik, MD, Peter Paschka, MD, Maria-Veronica Teleanu, MD, Karlheinz Holzmann, PhD, Gudrun Göhring, MD, Felicitas Thol, MD, Michael Heuser, MD, Arnold Ganser, MD PhD, Richard F. Schlenk, MD, Hartmut Döhner, Prof. Dr., Lars Bullinger, MD, Konstanze Döhner, MD

Blood (2015) 126 (23): 1381.

https://doi.org/10.1182/blood.V126.23.1381.1381

Published: 2015

Journal Articles

Mutational Landscape of Del(9q) Acute Myeloid Leukemia (AML)

Anna Dolnik, PhD, Sundaram R. Chakkarappan, PhD, Tamara J. Blätte, Sibylle Cocciardi, Jan Krönke, MD, Corbacioglu Andrea, PhD, Karlheinz Holzmann, PhD, Peter Paschka, MD, Frank G. Rücker, MD, Silke Kapp-Schwoerer, MD, Verena I. Gaidzik, MD, Richard F. Schlenk, MD, Hartmut Döhner, Prof. Dr., Konstanze Döhner, MD, Lars Bullinger, MD

Blood (2015) 126 (23): 3844.

https://doi.org/10.1182/blood.V126.23.3844.3844

Published: 2015

Journal Articles

Sequential Molecular Characterization Based Delineation of Potential Driver Aberrations in ACUTE Myeloid Leukemia Following Myelodysplastic Syndrome

Frank G. Rücker, MD, Sibylle Cocciardi, Anna Dolnik, PhD, Tamara J. Blätte, Ulrike Wüst, Peter Paschka, MD, Verena I. Gaidzik, MD, Richard F. Schlenk, MD, Hartmut Döhner, Prof. Dr., Lars Bullinger, MD, Konstanze Döhner, MD

Blood (2015) 126 (23): 4123.

https://doi.org/10.1182/blood.V126.23.4123.4123

Published: 2015

NARROW

Deregulated Expression of Circular RNAs in Acute Myeloid Leukemia

NGS-Based Monitoring of Measurable Residual Disease in FLT3 -ITD Positive Acute Myeloid Leukemia

Assessment of the Genomic Landscape of Intermediate Risk Acute Myeloid Leukemia As Defined By 2010 ELN Risk Classification

BRCA1/2 Containing Complex 3 ( BRCC36 ) Is Recurrently Mutated in AML with t(8;21) and Associated with Increased Sensitivity to Chemotherapy through Impairment of the DNA Damage Repair Pathway

Comprehensive Molecular Profiling of FLT3 -Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603)

Genetic Heterogeneity of t(8;21)(q22;q22.1) Acute Myeloid Leukemia Revealed By High-Throughput Targeted Sequencing

Clonal Evolution of FLT3 -ITD Positive AML in Patients Treated with Midostaurin in Combination with Chemotherapy within the Ratify (CALGB 10603) and AMLSG 16-10 Trials

Whole Exome Sequencing Reveals High Genetic Diversity in Relapsed Multiple Myeloma

High-Resolution SNP-Array Profiling of "Ultra-High Risk" CLL Cases Reveals New Recurrent Genomic Alterations

Circular RNAs of the Nucleophosmin 1 ( NPM1 ) Gene in Acute Myeloid Leukemia Patients

Impact of Gene Mutations on Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) Treated with Azacitidine (AZA) or Conventional Care Regimens (CCR)

Analysis of the PD-1/PD-L1 Axis Points to Association of Unfavorable Recurrent Mutations with PD-L1 Expression in AML

In Vivo modeling of Resistance to PI3Kδ Inhibitor Treatment Using EµTCL1-Tg Tumor Transfer Model

Clonal Evolution in NPM1 Mutated Acute Myeloid Leukemia (AML)

Mutational Landscape of Del(9q) Acute Myeloid Leukemia (AML)

Sequential Molecular Characterization Based Delineation of Potential Driver Aberrations in ACUTE Myeloid Leukemia Following Myelodysplastic Syndrome

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only